Immunotherapy News and Research

Latest Immunotherapy News and Research

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers.

14 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

Wake Forest Baptist Center provides tips to deal with springtime allergies

The return of spring marks the end of the cold and flu season, but the warmer weather and longer days present a different set of health issues.

13 Mar 2014

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune response, ultimately allowing solid tumors to act as their own cancer-fighting vaccine.

13 Mar 2014

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Tumor necrosis factor inhibitors (TNFis) are used to treat inflammatory conditions, such as RA. These agents work by blocking TNF, an important mediator of inflammation in RA, in order to help reduce inflammation and stop disease progression.

12 Mar 2014

Thirteen graduate students to receive 2014 Harold M. Weintraub Graduate Student Award

Thirteen graduate students from institutes throughout North America have been chosen to receive the 2014 Harold M. Weintraub Graduate Student Award sponsored by the Basic Sciences Division of Fred Hutchinson Cancer Research Center.

11 Mar 2014

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online today in Blood, the journal of the American Society of Hematology.

10 Mar 2014

BWH researchers explore newer approaches to treat Alzheimer's disease

A team of Alzheimer's disease (AD) researchers at Brigham and Women's Hospital (BWH) has been able to study the underlying causes of AD and develop assays to test newer approaches to treatment by using stem cells derived from related family members with a genetic predisposition to (AD).

7 Mar 2014

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development.

7 Mar 2014

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

A biomedical engineering researcher at the University of Arkansas will use a $416,897 grant from the National Cancer Institute to continue developing a new therapy for bladder cancer.

6 Mar 2014

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

A novel approach to cancer immunotherapy - strategies designed to induce the immune system to attack cancer cells - may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma.

6 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Merck, known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego.

5 Mar 2014

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.

5 Mar 2014

Local hyperthermia treatment induces mechanism of anti-tumor immune resistance

A combination of iron-oxide nanoparticles and an alternating magnetic field, which together generate heat, have activated an immune system response to tumors in mice according to an accepted manuscript by Dartmouth-Hitchcock Norris Cotton Center researchers in the journal Nanomedicine: Nanotechnology, Biology and Medicine released online on February 24, 2014.

5 Mar 2014

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

4 Mar 2014

Dendreon plans to make PROVENGE available in Europe

Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.

3 Mar 2014

Food allergy increases among black children, say researchers

Children's food allergies are gradually increasing, but they may be as much as doubling among black children. According to a study published today in the March issue of Annals of Allergy, Asthma and Immunology, the scientific publication of the American College of Allergy, Asthma and Immunology (ACAAI), self-reported food allergy nearly doubled in black children over 23 years.

3 Mar 2014

Washington University professor to receive AACR-CRI Lloyd J. Old Award in Cancer Immunology

The American Association for Cancer Research (AACR) and the Cancer Research Institute (CRI) will present Robert D. Schreiber, Ph.D., Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology, and Director of the Center for Human Immunology and Immunotherapy Programs at Washington University School of Medicine in St. Louis, Mo., with the second annual AACR-CRI Lloyd J. Old Award in Cancer Immunology at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.

3 Mar 2014

Asthma drug accelerates desensitization in patients with food allergies to several foods

An asthma drug accelerates the process of desensitizing patients with food allergies to several foods at the same time, a new study by researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford shows.

3 Mar 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

Wake Forest Baptist Center provides tips to deal with springtime allergies

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Thirteen graduate students to receive 2014 Harold M. Weintraub Graduate Student Award

A pill may provide hope to relapsed leukemia and lymphoma patients

BWH researchers explore newer approaches to treat Alzheimer's disease

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Researcher wins grant from NCI to continue developing new therapy for bladder cancer

Novel cancer immunotherapy approach may provide new weapon against most deadly tumors

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Local hyperthermia treatment induces mechanism of anti-tumor immune resistance

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

Dendreon plans to make PROVENGE available in Europe

Food allergy increases among black children, say researchers

Washington University professor to receive AACR-CRI Lloyd J. Old Award in Cancer Immunology

Asthma drug accelerates desensitization in patients with food allergies to several foods

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in